Pharsight

Crestor patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6858618

(Pediatric)

IPR Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
Jun, 2022

(1 year, 3 months ago)

Crestor is owned by Ipr.

Crestor contains Rosuvastatin Calcium.

Crestor has a total of 1 drug patent out of which 1 drug patent has expired.

Expired drug patents of Crestor are:

  • US6858618*PED

Crestor was authorised for market use on 12 August, 2003.

Crestor is available in tablet;oral dosage forms.

The generics of Crestor are possible to be released after 27 May, 2023.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 27, 2023

Drugs and Companies using ROSUVASTATIN CALCIUM ingredient

Market Authorisation Date: 12 August, 2003

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of CRESTOR before it's drug patent expiration?
More Information on Dosage

CRESTOR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic